Pulmonary Arterial Hypertension: 68-Market Analysis and Sales Forecast
Summary
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Pulmonary Arterial Hypertension market.
Across the 68 markets, sales in the PAH market were $10.1 billion in 2024, growing to $17.9 billion in 2034.
The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 24.5% and 48.0% in 68-market sales in 2024 and 2034, respectively.
Scope
- This publication is an expanded version of the Excel model containing the patient-based forecast sales for PAH, covered in GlobalData’s report “Pulmonary Arterial Hypertension: Seven-Market Drug Forecast and Market Analysis to 2034”, published in June 2025.
- In addition to patient based forecast sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 60 geographical markets (60M), totaling 68 markets (68M).
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM PAH therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM PAH therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- 1 Executive Summary
- 1.1 Overview
- 1.2 68M summary statistics
- 1.3 Key 7MM events driving the 68M forecast extrapolation
- 2 Appendix
- 2.1 Abbreviations
- 2.2 Methodology
- 2.2.1 Patient-based forecast methodology
- 2.2.2 68M forecast extrapolation methodology
- 2.3 Primary research - key opinion leaders and payers interviewed for this report
- 2.3.1 Key opinion leaders
- 2.4 Primary research - prescriber survey
- 2.5 About the authors
- 2.5.1 Therapy Area Director
- 2.5.2 Vice President of Disease Intelligence and Epidemiology
- 2.5.3 Global Head of Pharma Research, Analysis, and Competitive Intelligence
- About GlobalData
- Contact Us
- List of Tables
- Table 1: PAH market size across the 68M - 7MM versus 61M
- Table 2: PAH market size across the 68M - by geographical region
- Table 3: PAH, key events occurring in the 7MM driving forecast trajectory in the 68M
- Table 4: High-prescribing physicians (non-KOLs) surveyed, by country
- List of Figures
- Figure 1: PAH market size across the 68M - 7MM versus 61M
- Figure 2: PAH market size across the 68M - by geographical region
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook